vimarsana.com
Home
Live Updates
Artax Announces First Patient Dosed in Phase 2a Psoriasis Trial Evaluating AX-158 : vimarsana.com
Artax Announces First Patient Dosed in Phase 2a Psoriasis Trial Evaluating AX-158
/PRNewswire/ -- Artax Biopharma, Inc., a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases, today announces...
Related Keywords
Cambridge ,
Cambridgeshire ,
United Kingdom ,
Boston ,
Massachusetts ,
United States ,
Artax Biopharma ,
Jamesg Krueger ,
Rob Armstrong ,
Company Phase ,
Linkedin ,
Advent Life Sciences ,
Head Of The Laboratory For Investigative Dermatology ,
Prnewswire Artax Biopharma Inc ,
Rockefeller University ,
Efficacy Results Are Expected ,
Second Half ,
Class Nck Blocker ,
Autoimmune Disease ,
Broad Potential ,
Treat Many Autoimmune Diseases ,
Causing Immunosuppression ,
Diseases Remain ,
Significant Unmet Medical Need ,
Affecting Millions ,
Artax Chief Executive Officer ,
Investigative Dermatology ,
Artax Scientific Advisory Board ,
Sound Bioventures ,
Columbus Venture ,
Pharmaceuticals ,
Health Care Amp Hospitals ,
Medical Pharmaceuticals ,
Biotechnology ,
Clinical Trials Amp Medical Discoveries ,
vimarsana.com © 2020. All Rights Reserved.